Search

Your search keyword '"impurity profiling"' showing total 102 results

Search Constraints

Start Over You searched for: Descriptor "impurity profiling" Remove constraint Descriptor: "impurity profiling" Database MEDLINE Remove constraint Database: MEDLINE
102 results on '"impurity profiling"'

Search Results

1. Optimized analysis for related substances in spiramycin based on high performance liquid chromatography with hybrid particle column and characterization of its impurities by single heartcut two-dimensional liquid chromatography coupled with quadrupole time-of-flight mass spectrometer.

2. Analytical quality by design-based development of a capillary electrophoresis method for Omeprazole impurity profiling.

3. Identification, trace level quantification, and in silico assessment of potential genotoxic impurity in Famotidine.

4. Targeted and untargeted screening for impurities in losartan tablets marketed in Germany by means of liquid chromatography/high resolution mass spectrometry.

5. Identification, synthesis, and characterization of an unprecedented N-(2-carboxyethyl) adduct impurity in an injectable ganirelix formulation.

6. Optimization of elution conditions and comparison of emerging biocompatible columns on the resolving power and detection sensitivity of oligonucleotides by ion-pairing reversed-phase liquid chromatography mass spectrometry.

7. Investigation of aclidinium bromide degradation by stability-indicating HPLC methods, characterization of impurities by NMR, and identification of degradation products by LC-MS.

8. Development of multiple heartcutting two-dimensional liquid chromatography with ion-pairing reversed-phase separations in both dimensions for analysis of impurities in therapeutic oligonucleotides.

9. Organic impurity profiling of 3,4-methylenedioxyamphetamine (MDA) synthesised from helional.

10. Organic impurity profiling of fentanyl samples associated with recent clandestine laboratory methods.

11. Sustainable chromatographic quantitation of multi-antihypertensive medications: application on diverse combinations containing hydrochlorothiazide along with LC-MS/MS profiling of potential impurities: greenness and whiteness evaluation.

12. Highly sensitive liquid chromatographic method combined with online ion suppression to remove interfering anions and mass spectrometry for impurity profiling of paromomycin sulfate.

13. Polybutylene terephthalate-based stationary phase for ion-pair-free reversed-phase liquid chromatography of small interfering RNA. Part 1: Direct coupling with mass spectrometry.

14. Identification and Characterization of the Isomeric Impurity of the Fungicide "Cyazofamid".

15. Development of a rapid and validated stability-indicating UPLC-PDA method for concurrent quantification of impurity profiling and an assay of ipratropium bromide and salbutamol sulfate in inhalation dosage form.

16. Degradation pathways and impurity profiling of the anticancer drug apalutamide by HPLC and LC-MS/MS and separation of impurities using Design of Experiments.

17. An Overview of Advances in the Chromatography of Drugs Impurity Profiling.

18. Recent Progresses in Analytical Perspectives of Degradation Studies and Impurity Profiling in Pharmaceutical Developments: An Updated Review.

19. Alternative methods to assess the impurity profile of a monographed API using acarbose as an example.

20. Analysis of impurity profiling of arbekacin sulfate by ion-pair liquid chromatography coupled with pulsed electrochemical detection and online ion suppressor-ion trap-time off light mass spectrometry.

21. Stability-indicating liquid chromatography method development for assay and impurity profiling of amitriptyline hydrochloride in tablet dosage form and forced degradation study.

22. Impurity Profiling of Dinotefuran by High Resolution Mass Spectrometry and SIRIUS Tool.

23. Impurity profiling of methamphetamine synthesized from methyl α-acetylphenylacetate.

24. Analytical Performance and Greenness Evaluation of Five Multi-Level Design Models Utilized for Impurity Profiling of Favipiravir, a Promising COVID-19 Antiviral Drug.

25. Chemical forensic profiling and attribution signature determination of sarin nerve agent using GC-MS, LC-MS and NMR.

26. Stability-indicating liquid chromatography method development and validation for impurity profiling of montelukast sodium in bulk drug and tablet dosage form.

27. Synthesis, characterization and control of eight process-related and two genotoxic fingolimod impurities by a validated RP-UPLC method.

28. Enrichment and purification of peptide impurities using twin-column continuous chromatography.

29. Advanced chemometric methods as powerful tools for impurity profiling of drug substances and drug products: Application on bisoprolol and perindopril binary mixture.

30. Capillary electrophoresis methods for impurity profiling of drugs: A review of the past decade.

31. Using thermal forced degradation approach for impurity profiling of budesonide solution-formulated metered dose inhalation with implementation of LC-QTOFMS and HPLC-UV.

32. Impurities, adulterants and cutting agents in cocaine as potential candidates for retrospective mining of GC-MS data.

33. Impurity profiling of methamphetamine synthesised from α-phenylacetoacetonitrile (APAAN).

34. Impurity profiling and stability-indicating method development and validation for the estimation of assay and degradation impurities of midostaurin in softgel capsules using HPLC and LC-MS.

35. Single quad mass analyzer coupled UPLC method for impurity profile of Brimonidine tartrate and Timolol maleate: Application in their binary mixture ophthalmic formulation.

36. Development of an efficient stability-indicating LC-MS/MS method for the analysis of selexipag and characterization of its degradation products.

37. The nitrosamine contamination of drugs, part 3: Quantification of 4-Methyl-1-nitrosopiperazine in rifampicin capsules by LC-MS/HRMS.

38. Greenness profile assessment of selective liquid chromatographic methods for determination of a quaternary antimigraine combination along with three of their related official impurities.

39. Impurity profiling of dapsone using gradient HPLC method.

40. Impurity profiling of siRNA by two-dimensional liquid chromatography-mass spectrometry with quinine carbamate anion-exchanger and ion-pair reversed-phase chromatography.

41. Investigating the chemical impurity profiles of fentanyl preparations and precursors to identify chemical attribution signatures for synthetic method attribution.

42. Measuring atropisomers of BMS-986142 using 2DLC as an enabling technology.

43. Impurity profiling of Cefteram pivoxil based on Fourier transform ion cyclotron resonance MS.

44. A multi-technique analytical approach for impurity profiling during synthesis: The case of difluprednate.

45. A selective comprehensive reversed-phase×reversed-phase 2D-liquid chromatography approach with multiple complementary detectors as advanced generic method for the quality control of synthetic and therapeutic peptides.

46. Impurity profiling high-performance-thin-layer chromatography method involving the assay of essential human micronutrient niacin with eco-scale assessment.

47. Impurity profiling of l-aspartic acid and glycine using high-performance liquid chromatography coupled with charged aerosol and ultraviolet detection.

48. The identification of chemical attribution signatures of stored VX nerve agents using NMR, GC-MS, and LC-HRMS.

49. Combination of stable isotope ratio data and chromatographic impurity signatures as a comprehensive concept for the profiling of highly prevalent synthetic cannabinoids and their precursors.

50. Mixed-mode chromatography characteristics of chiralpak ZWIX(+) and ZWIX(-) and elucidation of their chromatographic orthogonality for LC × LC application.

Catalog

Books, media, physical & digital resources